The non-peptide pill that hijacks the ghrelin receptor to release growth hormone—and what eleven human trials reveal about what it actually does to your body

MK-677 holds a unique position in the growth hormone secretagogue landscape: it is the only compound in this class that you swallow instead of inject. That distinction matters more than convenience. Because MK-677 is a small molecule—not a peptide—it survives the digestive tract intact and produces growth hormone elevation that lasts roughly 24 hours per dose, fundamentally different from the brief 2-hour pulses generated by injectable peptide secretagogues like ipamorelin or GHRP-2.

That pharmacological difference has consequences. The pituitary gland evolved to release growth hormone in pulses, not in a sustained stream. Whether MK-677's continuous profile is an advantage or a liability depends on what you are measuring—and the answer changes depending on whether you are looking at lean mass, sleep architecture, insulin sensitivity, or cardiac risk.

What makes MK-677 unusual on a site dedicated to peptide research is that it has more published human clinical data than almost anything else we cover. Eleven controlled trials across populations ranging from healthy young men to elderly Alzheimer's patients. A year-long body composition study. A 563-person multicenter trial that was stopped early—not because it worked, but because of a safety signal. This is not a compound where we have to guess what might happen in humans. We know. And the picture is more complicated than either its advocates or its critics suggest.

Lumos Pharma is currently running a Phase 3 trial of MK-677 (branded as LUM-201) for children with growth hormone deficiency—the most advanced clinical program for any GH secretagogue in 2026.

Quick Facts: MK-677 at a Glance

What Is MK-677 (Ibutamoren)?

Pronunciation: em-kay-six-seventy-seven / ih-BYOO-tah-MOR-en (also known as Ibutamoren, Ibutamoren Mesylate, L-163191, LUM-201)

Your pituitary gland releases growth hormone in pulses—sharp spikes that last about two hours each, primarily during deep sleep. Every injectable peptide secretagogue on this site works by triggering those pulses. MK-677 does something different. It activates the same receptor—GHS-R1a, the ghrelin receptor—but because it is a small molecule that survives digestion and lingers in the bloodstream for nearly 24 hours, it produces a fundamentally different pattern: sustained elevation rather than pulsatile release.

This is not a trivial pharmacological distinction. The pituitary's pulse pattern exists for a reason—GH pulses drive different downstream effects than continuous GH exposure. Injectable recombinant GH (which produces sustained levels) and GH secretagogues (which produce pulses) do not produce identical clinical outcomes, even at similar total GH exposure. Where MK-677 falls on this spectrum is one of the central questions of its pharmacology.

MK-677 was developed by Merck Research Laboratories in the early 1990s as part of a systematic effort to create an orally bioavailable growth hormone secretagogue. The compound emerged from structure-activity relationship studies on benzolactam derivatives and was optimized into the spiroindoline scaffold that defines its chemical class. Its molecular weight is 624.8 Da—large for a small molecule, but structurally nothing like a peptide.

Origins and Discovery

The search for an orally active growth hormone secretagogue began in the late 1970s when Cyril Bowers at Tulane University discovered that small synthetic peptides could trigger GH release from the pituitary through a receptor that was not the known GHRH receptor. This receptor—later identified as GHS-R1a and recognized as the ghrelin receptor—became a pharmaceutical target.

Merck's medicinal chemistry team, led by Arthur Patchett, systematically transformed the peptide GHRP-6 into progressively smaller, non-peptide mimetics. The critical breakthrough was the benzolactam scaffold (L-692,429), which proved that a non-peptide could activate GHS-R1a. Further optimization produced L-692,585 and eventually MK-677 (L-163,191), a spiroindoline with oral bioavailability, a long pharmacodynamic half-life, and selectivity for the growth hormone axis.

Merck conducted an extensive Phase II clinical program through the late 1990s and 2000s, testing MK-677 across at least seven distinct patient populations. Despite consistent pharmacodynamic effects—GH and IGF-1 reliably increased in every trial—Merck never filed a New Drug Application. The likely reasons: the insulin resistance signal was dose-dependent and persistent, the largest trial (Alzheimer's, n=563) failed its primary endpoint and revealed a heart failure signal, and the competitive landscape shifted as recombinant GH became the standard of care.

The compound resurfaced when Lumos Pharma acquired the rights and began developing it as LUM-201 for pediatric growth hormone deficiency—using a "predictive enrichment marker" strategy to identify children most likely to respond. That Phase 3 trial (OraGrowtH, NCT06948214) is currently recruiting as of 2025–2026.

Mechanism of Action

MK-677 activates the growth hormone secretagogue receptor type 1a (GHS-R1a)—the same receptor that binds ghrelin, the endogenous hunger hormone. GHS-R1a is a G-protein-coupled receptor expressed primarily on pituitary somatotrophs and hypothalamic neurons.

At the pituitary: GHS-R1a activation triggers the Gq/11 → phospholipase C → IP3 → intracellular calcium cascade in somatotroph cells. The calcium flux directly stimulates growth hormone vesicle exocytosis. This is the same pathway activated by ghrelin and by every GHRP (GHRP-2, GHRP-6, hexarelin, ipamorelin). The difference is duration: injectable peptide agonists produce a pulse lasting ~2 hours; MK-677's ~24-hour pharmacodynamic half-life produces sustained receptor activation.

At the hypothalamus: MK-677 suppresses somatostatin tone. Somatostatin is the pituitary's brake pedal—it inhibits GH release. By reducing somatostatin secretion from the periventricular nucleus, MK-677 amplifies GH output through a dual mechanism: directly stimulating release AND removing the inhibitory brake. This is shared with other GHS-R1a agonists but is particularly relevant for MK-677 because its sustained presence means sustained somatostatin suppression.

What MK-677 does NOT do: It does not activate the GHRH receptor (GHRHR). GHRH and ghrelin/GHS-R1a operate through separate signaling cascades that converge at the somatotroph. This is why combining a GHS-R1a agonist (like MK-677) with a GHRH analog (like CJC-1295 or sermorelin) produces synergistic GH release—they activate complementary pathways. Combining MK-677 with another GHS-R1a agonist like ipamorelin is pharmacologically redundant—they compete for the same receptor.

The ghrelin receptor problem: GHS-R1a is not exclusively a growth hormone switch. It is the ghrelin receptor—the receptor that mediates hunger, gastric motility, glucose homeostasis, and reward circuitry. Activating GHS-R1a to release growth hormone simultaneously activates all of ghrelin's other downstream effects. Appetite stimulation, the most common "side effect" reported by MK-677 users, is not a side effect at all. It is the primary function of the receptor being activated. You cannot cleanly separate GH release from appetite stimulation through GHS-R1a.

Key Research Areas and Studies

Body Composition and Lean Mass

The body composition data is MK-677's strongest evidence domain. Multiple RCTs consistently show increases in fat-free mass (FFM), though the clinical significance of these changes is nuanced.

The landmark study is Nass et al. 2008 (PMID 18981485)—a 12-month, double-blind, placebo-controlled trial in 65 healthy older adults (60–81 years). This is the most rigorous and longest body composition trial for any GH secretagogue. Results: FFM increased by 1.1 kg (P<0.001) over 12 months. However—and this is the critical caveat—there was NO improvement in muscle strength or physical function. The lean mass was "non-functional"—likely water and non-contractile protein rather than contractile muscle fiber. Quality of life measures showed no improvement.

Chapman et al. 1996 (PMID 8954023) established the dose-response relationship in 32 healthy elderly subjects. The 25 mg dose was identified as optimal—producing significant GH/IGF-1 elevation with manageable side effects. This study also documented the appetite stimulation and peripheral edema that recur across every subsequent trial.

Svensson et al. 1998 (PMID 9519218) tested MK-677 in 24 obese men for 2 months. FFM increased and energy expenditure increased, but fat mass did not significantly decrease. This is consistent with the Nass finding: MK-677 adds lean mass but does not reliably reduce fat mass in the timeframes studied.

Murphy et al. 1998 (PMID 9467534) demonstrated that MK-677 reversed nitrogen wasting during caloric restriction in 8 healthy young men—a crossover RCT showing anti-catabolic effects during dieting. This is the primary evidence basis for the community's use of MK-677 during cutting phases.

Sleep Quality

Copinschi et al. 1997 (PMID 9349662) is the best-controlled sleep study for any GH secretagogue. In a double-blind RCT of 14 subjects (8 young, 6 older), MK-677 at 25 mg/day for 1 week increased both slow-wave sleep (Stage III and IV) duration and REM sleep duration. This is the most direct evidence linking GH secretagogue use to sleep architecture improvement—and it is frequently cited by the community as a primary reason for MK-677 use.

The mechanism is plausible: GH is primarily released during slow-wave sleep, and GHS-R1a activation in the hypothalamus may directly modulate sleep architecture through orexin and GABA pathways. However, this is a single small study of one week's duration, and no long-term sleep data exist.

Bone Metabolism

Murphy et al. 1999 (PMID 10404019) showed that 9 weeks of MK-677 in elderly subjects increased bone turnover markers—osteocalcin and bone-specific alkaline phosphatase—suggesting increased bone formation. Adunsky et al. 2011 (PMID 21195559) tested MK-677 in 123 elderly hip fracture patients over 6 months: lean mass was preserved and there were trends toward functional improvement, but the MK-677 group had higher dropout rates due to edema and glucose elevation. Neither study measured bone density directly (only markers), so the clinical relevance for fracture prevention remains unestablished.

Growth Hormone Deficiency

Bach et al. 1997 (PMID 9329386) demonstrated that MK-677 stimulated the GH/IGF-1 axis in GH-deficient adults, but response depended on residual GH secretory capacity. Bowers et al. 2001 (PMID 11452249) showed oral MK-677 was active in GH-deficient children. These studies form the basis for Lumos Pharma's LUM-201 program, which uses a "predictive enrichment marker" (PEM)—baseline IGF-1 response to a test dose—to identify children who will respond to oral MK-677 instead of daily GH injections. The Phase 2 trial (NCT04614337) demonstrated that PEM-selected children achieved normal GH levels, and the Phase 3 OraGrowtH trial (NCT06948214) is currently recruiting.

The Alzheimer's Failure and Heart Failure Signal

Sevigny et al. 2008 (PMID 19015485) is the largest RCT for any compound in Cluster D: 563 patients with mild-to-moderate Alzheimer's disease, double-blind, placebo-controlled, 12 months. The hypothesis was that raising IGF-1 might slow cognitive decline—a plausible theory given IGF-1's role in neuronal survival and synaptic plasticity.

The trial was terminated early for futility. MK-677 successfully raised IGF-1 but produced zero cognitive benefit. More critically, the MK-677 group had a significantly higher rate of congestive heart failure: 6.5% versus 1.7% in the placebo group. This was in an elderly population with known cardiovascular vulnerability, and the absolute numbers were small. But it is a statistically significant safety signal that cannot be dismissed—and it is the likely reason Merck never pursued regulatory approval.

The Pulsatile vs. Sustained Question

This compound-specific section addresses the central pharmacological question that distinguishes MK-677 from every injectable secretagogue in Cluster D.

The pituitary gland releases growth hormone in discrete pulses—approximately 6–12 per day, with the largest occurring during deep sleep. This pulsatile pattern is not arbitrary. Downstream tissues respond differently to pulsed versus continuous GH exposure. In rodent models, pulsatile GH drives sexually dimorphic liver gene expression, linear growth, and lean mass accrual more effectively than continuous infusion at the same total dose.

Injectable peptide secretagogues (ipamorelin, GHRP-2, GHRP-6, hexarelin) produce GH pulses that last approximately 2 hours—mimicking the natural pattern. MK-677's ~24-hour pharmacodynamic half-life means it produces sustained GH elevation that more closely resembles continuous GH infusion than natural pulsatile secretion.

This creates a genuine pharmacological dilemma. Some of MK-677's documented effects—appetite stimulation, insulin resistance, edema—may be consequences of sustained rather than pulsatile GH/IGF-1 elevation. The Nass 2008 finding that lean mass increased without strength improvement could reflect continuous GH's tendency to promote water retention and non-contractile protein synthesis rather than the myofibrillar hypertrophy that pulsatile GH promotes.

No head-to-head trial has compared MK-677 to an injectable secretagogue on body composition, sleep, or metabolic outcomes. This comparison—pulsatile versus sustained—is the most important unanswered question in GH secretagogue pharmacology.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Chapman et al. 1996 — The Dose-Finding Study

Design: Randomized, double-blind, placebo-controlled. N: 32 healthy elderly adults (64–81 years). Duration: Single-dose + multi-dose escalation. Key findings: 25 mg identified as optimal dose. GH and IGF-1 increased dose-dependently. Appetite stimulation and peripheral edema documented. Limitations: Short duration. Healthy volunteers—not a treatment population. PMID: 8954023

Patchett/Thorner et al. 1995 — The 24-Hour GH Profile

Design: Randomized, double-blind. N: 9 healthy young men. Duration: 7 days. Key findings: 24-hour GH profiling confirmed sustained elevation (not pulsatile). IGF-1 increased. ACTH and cortisol unaffected at GH-stimulating doses—confirming adrenocortical selectivity. Limitations: Very small sample. Young healthy males only. PMID: 8768828

Copinschi et al. 1997 — The Sleep Study

Design: Randomized, double-blind, placebo-controlled. N: 14 (8 young, 6 older) healthy men. Duration: 7 days at 25 mg/day. Key findings: Increased slow-wave sleep (Stage III/IV) duration by ~50%. Increased REM sleep. GH secretion during sleep increased. Limitations: Single study. 14 subjects. One week only. No long-term sleep data exist. PMID: 9349662

Murphy et al. 1998 — The Anti-Catabolic Study

Design: Randomized, double-blind, crossover. N: 8 healthy young men. Duration: 7 days during caloric restriction. Key findings: Reversed nitrogen wasting during a caloric deficit. Protein-sparing effect confirmed by nitrogen balance. Limitations: 8 subjects. 7 days. Artificial caloric restriction protocol, not real-world dieting. PMID: 9467534

Svensson et al. 1998 — The Obesity Study

Design: Randomized, double-blind, placebo-controlled. N: 24 obese men. Duration: 2 months. Key findings: FFM increased. Energy expenditure increased. Fat mass did NOT significantly decrease. GH/IGF-1 increased. Limitations: Short duration. Obese men only—not generalizable. No fat loss despite increased energy expenditure. PMID: 9519218

Bach et al. 1997 — GH-Deficient Adults

Design: Randomized, placebo-controlled. N: 29 GH-deficient adults. Duration: 2–4 weeks. Key findings: MK-677 stimulated GH/IGF-1 in selected GHD adults. Response depended on residual GH secretory capacity—patients with severe GHD (no residual capacity) did not respond. Limitations: Small sample. Short duration. Heterogeneous GHD severity. PMID: 9329386

Nass et al. 2008 — The 12-Month Body Composition Study

Design: Randomized, double-blind, placebo-controlled. N: 65 healthy older adults (60–81 years). Duration: 12 months. Key findings: FFM increased by 1.1 kg (P<0.001). GH and IGF-1 sustained at younger-adult levels for 12 months. NO improvement in strength. NO improvement in physical function. NO improvement in quality of life. Fasting glucose and insulin both increased (persistent insulin resistance). Limitations: Healthy elderly—not a disease population. Small sample for a 12-month study. The lack of functional improvement despite lean mass gain is the central interpretive challenge. PMID: 18981485

Murphy et al. 1999 — The Bone Marker Study

Design: Randomized, placebo-controlled. N: 32 elderly + 29 functionally impaired adults. Duration: 9 weeks. Key findings: Increased osteocalcin and bone-specific alkaline phosphatase (bone formation markers). Limitations: Markers only—no bone density or fracture data. 9 weeks—too short for bone remodeling cycle (4–6 months minimum). PMID: 10404019

Adunsky et al. 2011 — The Hip Fracture Study

Design: Randomized, multicenter, double-blind, placebo-controlled. N: 123 elderly hip fracture patients. Duration: 6 months. Key findings: Lean mass preserved in MK-677 group. Trends toward improved functional outcomes (gait speed, stair climbing). Higher dropout in MK-677 group due to edema and glucose elevation. Limitations: High dropout reduces interpretability. Trends—not statistically significant functional improvement. Elderly, frail population—not generalizable. PMID: 21195559

Sevigny et al. 2008 — The Alzheimer's Trial

Design: Randomized, double-blind, placebo-controlled, multicenter. N: 563 patients with mild-to-moderate Alzheimer's disease. Duration: 12 months (terminated early for futility). Key findings: IGF-1 increased successfully. ZERO cognitive benefit on ADAS-Cog or CIBIC+ scales. Congestive heart failure: 6.5% MK-677 group vs. 1.7% placebo (statistically significant). Limitations: Elderly population with pre-existing cardiovascular vulnerability. The heart failure signal may not extrapolate to younger, healthier populations—but it cannot be ignored. PMID: 19015485

Bowers et al. 2001 — GH-Deficient Children

Design: Open-label, dose-finding. N: ~30 GH-deficient children. Key findings: Oral MK-677 stimulated GH/IGF-1 in GHD children. Basis for LUM-201 development. Limitations: Open-label. Dose-finding—not efficacy trial. PMID: 11452249

LUM-201 / OraGrowtH — Active Phase 3 (2025–2026)

Sponsor: Lumos Pharma. Design: Randomized controlled trial with predictive enrichment marker. Population: Pediatric GHD. ClinicalTrials.gov: NCT06948214 (Phase 3), NCT04614337 (Phase 2, completed). Phase 2 results: PEM-selected children achieved restoration to normal GH range. Status: Recruiting as of 2025.

Safety, Risks, and Limitations

Insulin Resistance and Glucose Elevation

This is the most consistently documented adverse effect across the MK-677 trial program. Fasting glucose and insulin increase in a dose-dependent manner. The Nass 2008 study confirmed this is sustained—not transient—over 12 months. In patients with pre-existing glucose intolerance or diabetes risk factors, MK-677 can precipitate clinically significant hyperglycemia. This is not surprising: GH is a counter-regulatory hormone that opposes insulin's action on glucose uptake. Raising GH continuously for 24 hours per dose amplifies this effect.

Congestive Heart Failure Signal

The Sevigny 2008 Alzheimer's trial documented a CHF rate of 6.5% in the MK-677 group versus 1.7% in the placebo group over 12 months. This was in elderly patients (mean age ~75) with pre-existing cardiovascular vulnerability, and the absolute numbers were small (19 events in the MK-677 group vs. 5 in the placebo group). The mechanism is plausible: GH and IGF-1 both promote sodium and water retention, which increases cardiac preload—a known trigger for heart failure in vulnerable individuals. Whether this signal is relevant to younger, healthy users at typical community doses (10–25 mg) is unknown. It has not been studied. But the signal exists, and the existing article underemphasizes it.

Appetite Stimulation

GHS-R1a IS the ghrelin receptor. Activating it to release GH simultaneously activates the hunger-signaling pathway. Appetite increase is not a side effect of MK-677—it is a primary pharmacological action of the target receptor. This distinction matters because it means appetite stimulation cannot be "dosed around" or mitigated by timing alone—it is intrinsic to the mechanism.

Peripheral Edema

Water retention is documented across multiple trials and is the most common reason for dropout. It is consistent with GH/IGF-1-mediated sodium retention and typically dose-dependent.

Hepatotoxicity (New Data — 2025)

A 2025 case report (PMID 40675653) documented elevated liver enzymes in a healthy male in his early 30s after 2 months of MK-677 use. Enzymes normalized after cessation. This is a single case and does not establish a causal relationship, but it is the first published hepatotoxicity signal and should be noted.

Hair Detection for Anti-Doping (2025)

A 2025 study (PMID 40882886) developed an LC-MS/MS method capable of detecting a single 10 mg MK-677 dose in hair samples. This has implications for competitive athletes and anyone subject to WADA-governed anti-doping testing.

What Is NOT Known

• Long-term safety beyond 12 months in any population
• Cardiovascular effects in young, healthy adults
• Interaction with exogenous testosterone, thyroid hormones, or other commonly co-administered compounds
• Cancer risk from sustained IGF-1 elevation (theoretical concern based on epidemiological associations between high IGF-1 and cancer risk—no MK-677-specific data)

Legal and Regulatory Status

MK-677 occupies a unique regulatory position in the GH secretagogue class. Because it is not a peptide, the FDA's 503A/503B compounding pharmacy regulations that affect injectable peptide secretagogues (ipamorelin, CJC-1295, etc.) do not directly apply. However:

• FDA status: Not approved for any indication. Never submitted for NDA. Category 3 on the FDA bulk drug substance evaluation list (meaning it is not eligible for compounding under Section 503A). LUM-201, the branded version, is in Phase 3 for pediatric GHD.
• DEA scheduling: Not a scheduled controlled substance.
• WADA status: Prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Banned both in-competition and out-of-competition. The 2025 hair detection method extends the detection window significantly.
• Legal sales channel: Sold widely online as a "research chemical." Not legal as a dietary supplement (it is a synthetic drug candidate, not a nutrient or botanical). The legal basis for consumer purchase is the research chemical exemption, which is thin and legally contested.

Research Protocols and Formulation Considerations

MK-677 is typically sold as: - Capsules: 10 mg or 25 mg. Most common consumer form. Quality varies dramatically by manufacturer. - Liquid solution: Dissolved in PEG-400 or similar vehicle. Allows dose titration. - Raw powder: Requires analytical verification. Counterfeiting is widespread—LC-MS analysis of "MK-677" products has found underdosed, overdosed, and contaminated samples.

Formulation considerations: - Oral administration. No reconstitution or injection required. - Food does not significantly affect absorption (based on clinical trial protocols that used both fasted and fed dosing). - Evening dosing is common in clinical trials (to align peak GH release with the natural nocturnal GH pulse) and in community protocols.

Dosing in Published Research

The following table summarizes dosing protocols for MK-677 as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Summary: The established research dose is 25 mg/day oral for adults, taken once daily (typically evening). This dose was used in all major adult trials. The pediatric GHD dose (LUM-201) is weight-based at 1.6 mg/kg/day.

Dosing in Self-Experimentation Communities

Community dosing protocols for MK-677 are well-documented due to the compound's oral bioavailability and widespread availability:

• Standard community dose: 10–25 mg/day, taken once daily in the evening
• Starting dose: Many community protocols recommend starting at 10 mg/day for 1–2 weeks to assess appetite and edema response before increasing to 25 mg
• Cycle length: 8–12 weeks is the most common community protocol. Some users report continuous use for 6+ months.
• Cycle-off periods: Community consensus generally recommends 4–8 week breaks between cycles, though the pharmacological basis for specific cycle lengths is not established in published research.
• Combination stacks: Frequently combined with ipamorelin (NOTE: this is pharmacologically redundant—both are GHS-R1a agonists competing for the same receptor) or with CJC-1295 (no DAC) (which activates GHRHR, a complementary pathway—this combination has pharmacological rationale)
• Blood glucose monitoring: Experienced community users typically recommend monitoring fasting glucose during MK-677 use, particularly at 25 mg/day and beyond
• Common reported experiences: Increased appetite (nearly universal), improved sleep quality (very common), water retention/bloating (common in first 2–4 weeks), vivid dreams (commonly reported), numbness/tingling in hands (carpal tunnel symptoms from fluid retention)

No controlled human trial has validated any community dosing protocol, cycle length, or combination stack for MK-677. The 25 mg/day dose matches published research; the cycling, stacking, and mitigation strategies are based on community experience, not clinical evidence.

Combination Stacks

Research into MK-677 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining MK-677 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

MK-677 stands apart in the growth hormone secretagogue class for two reasons: it is the only compound you swallow instead of inject, and it has more published human clinical data than almost any other compound on this site. Eleven controlled trials in 929 subjects have established what MK-677 does—and equally importantly, what it does not do.

What MK-677 reliably does: it raises growth hormone and IGF-1, increases fat-free mass, improves slow-wave and REM sleep, reverses nitrogen wasting during caloric restriction, and increases bone turnover markers. These effects are reproducible across multiple independent research groups.

What MK-677 does not do: it does not increase muscle strength (the most rigorous 12-month study showed zero functional improvement), it does not reduce fat mass in the timeframes studied, it does not improve cognitive function in Alzheimer's patients, and it does not do any of the above without simultaneously increasing appetite, raising blood sugar, causing water retention, and—in elderly populations—potentially increasing heart failure risk.

The compound that Merck spent over a decade developing and never filed for approval is now available on every peptide vendor website, sold to consumers who largely lack access to the full clinical picture. That picture is not discouraging—it is genuinely nuanced. MK-677 has real effects documented by real science. It also has real risks documented by the same science. Whether the trade-off is worthwhile depends on individual goals, risk tolerance, and metabolic baseline.

Verdict Recapitulation

MK-677 earns a Reasonable Bet verdict because the evidence base is large enough to know both what it does and what it costs. The GH/IGF-1 elevation is robust and reproducible. The lean mass increase is documented but non-functional. The sleep data is promising but thin. The insulin resistance is persistent. The heart failure signal is real. Merck walked away. Lumos Pharma is running a Phase 3 trial for a specific, narrow indication (pediatric GHD) using enrichment markers to select responders—a strategy that implicitly acknowledges the compound does not work for everyone.

This is not a compound where we are guessing about what happens in humans. We know. And the knowing is more complicated than either the hype or the dismissal suggests.

For readers considering MK-677, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source MK-677

Further Reading and Resources

If you want to go deeper on MK-677, the evidence landscape for growth hormone secretagogues peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Growth Hormone Secretagogues Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: MK-677 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249–4257. PMID 8954023
2. Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA. 1995;92(15):7001–7005. PMID 8768828
3. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278–286. PMID 9349662
4. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320–325. PMID 9467534
5. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362–369. PMID 9519218
6. Bach MA, Rockwood K, Zetterberg C, et al. The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture. J Am Geriatr Soc. 2004;52(4):516–523. NOTE: This is the Adunsky 2011 study group's earlier analysis. PMID 9329386 (Bach 1997 GHD adult study)
7. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601–611. PMID 18981485
8. Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. J Bone Miner Res. 1999;14(suppl 1):S161. PMID 10404019
9. Adunsky A, Chandler J, Heyden N, et al. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Arch Gerontol Geriatr. 2011;53(2):183–189. PMID 21195559
10. Sevigny JJ, Ryan JM, van Dyck CH, et al. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21):1702–1708. PMID 19015485
11. Bowers CY, Granda-Ayala R, et al. Growth hormone (GH) releasing peptides (GHRPs) and the GH secretagogue receptor (GHS-R) in GH-deficient children. Horm Res. 2001;56(suppl 1):33–38. PMID 11452249
12. Hepatotoxicity case report (2025). PMID 40675653
13. Hair detection method for anti-doping (2025). PMID 40882886

---